Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy.

IF 5.4 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Communications medicine Pub Date : 2025-08-29 DOI:10.1038/s43856-025-01102-3

Mayumi Niimura, Yasuhisa Sakamoto, Mayuko Shimoda, Narumi Harada, Ayato Maeda, Shiho Wada, Koki Murata, Chanida Thinyakul, Saisai Liu, Haruka Ohara, Asuka Iwamoto, Yohei Kanamori, Akihiro Nita, Masahiro Wakao, Yasuo Suda, Hiroyuki Oshiumi, Tomoko Hayashi, Dennis A Carson, Hiroyuki Shinchi, Toshiro Moroishi

{"title":"Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy.","authors":"Mayumi Niimura, Yasuhisa Sakamoto, Mayuko Shimoda, Narumi Harada, Ayato Maeda, Shiho Wada, Koki Murata, Chanida Thinyakul, Saisai Liu, Haruka Ohara, Asuka Iwamoto, Yohei Kanamori, Akihiro Nita, Masahiro Wakao, Yasuo Suda, Hiroyuki Oshiumi, Tomoko Hayashi, Dennis A Carson, Hiroyuki Shinchi, Toshiro Moroishi","doi":"10.1038/s43856-025-01102-3","DOIUrl":null,"url":null,"abstract":"Background: Cancer immunotherapy, particularly using immune checkpoint inhibitors, has revolutionized cancer treatment; however, its efficacy remains limited to a subset of patients. Nanoparticles have potential in cancer treatment because they offer advantages such as biocompatibility, greater stability, and precise targeting capabilities.Method: We synthesized an integrated glyco-nanovaccine (iGN) comprising gold nanoparticles conjugated with a synthetic Toll-like receptor 7 (TLR7) ligand, sugar chains, and peptide antigens for cancer immunotherapy. The potential of iGN was investigated using a therapeutic animal model.Results: In murine models, iGN effectively induces antigen-specific cytotoxic T cells, demonstrating prophylactic and therapeutic efficacy against tumor growth. iGN stimulates antigen-presenting cells via the TLR7-MYD88 pathway, enhancing antigen presentation and priming of cytotoxic T cells. Combination therapy with iGN and anti-PD-1 antibodies improves survival of tumor-bearing mice.Conclusions: These findings underscore the potential of iGN as a strategy to enhance cancer immunotherapy, particularly when used in combination with immune checkpoint blockade, to bolster anti-tumor immune responses and improve therapeutic outcomes.","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"378"},"PeriodicalIF":5.4000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397435/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communications medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s43856-025-01102-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer immunotherapy, particularly using immune checkpoint inhibitors, has revolutionized cancer treatment; however, its efficacy remains limited to a subset of patients. Nanoparticles have potential in cancer treatment because they offer advantages such as biocompatibility, greater stability, and precise targeting capabilities.

Method: We synthesized an integrated glyco-nanovaccine (iGN) comprising gold nanoparticles conjugated with a synthetic Toll-like receptor 7 (TLR7) ligand, sugar chains, and peptide antigens for cancer immunotherapy. The potential of iGN was investigated using a therapeutic animal model.

Results: In murine models, iGN effectively induces antigen-specific cytotoxic T cells, demonstrating prophylactic and therapeutic efficacy against tumor growth. iGN stimulates antigen-presenting cells via the TLR7-MYD88 pathway, enhancing antigen presentation and priming of cytotoxic T cells. Combination therapy with iGN and anti-PD-1 antibodies improves survival of tumor-bearing mice.

Conclusions: These findings underscore the potential of iGN as a strategy to enhance cancer immunotherapy, particularly when used in combination with immune checkpoint blockade, to bolster anti-tumor immune responses and improve therapeutic outcomes.

查看原文本刊更多论文

利用糖纳米疫苗集成技术增强癌症免疫治疗。

背景：癌症免疫治疗，特别是使用免疫检查点抑制剂，已经彻底改变了癌症治疗；然而，它的疗效仍然局限于一小部分患者。纳米粒子在癌症治疗中具有潜力，因为它们具有诸如生物相容性、更高的稳定性和精确靶向能力等优点。方法：我们合成了一种整合糖纳米疫苗（iGN），该疫苗由金纳米颗粒与合成toll样受体7 （TLR7）配体、糖链和肽抗原结合而成，用于癌症免疫治疗。用治疗性动物模型研究了iGN的潜力。结果：在小鼠模型中，iGN能有效诱导抗原特异性细胞毒性T细胞，显示出对肿瘤生长的预防和治疗作用。iGN通过TLR7-MYD88途径刺激抗原提呈细胞，增强抗原提呈和细胞毒性T细胞的启动。iGN和抗pd -1抗体联合治疗可提高荷瘤小鼠的生存率。结论：这些发现强调了iGN作为一种增强癌症免疫治疗策略的潜力，特别是当与免疫检查点阻断联合使用时，可以增强抗肿瘤免疫反应并改善治疗结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Communications medicine

自引率

0.00%

发文量